Caribou Biosciences, Inc. (NASDAQ:CRBU) Stock Now Rated “Hold” by Sell-Side Brokerages

by · The Markets Daily

Caribou Biosciences, Inc. (NASDAQ:CRBU – Get Free Report) has received an average rating of “Hold” from the eight analysts that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $5.50.

A number of analysts have recently commented on the company. Leerink Partners reissued a “market perform” rating and set a $1.00 price target (down from $4.00) on shares of Caribou Biosciences in a research note on Wednesday, October 7th. HC Wainwright cut shares of Caribou Biosciences from a “buy” rating to a “neutral” rating in a research report on Thursday, October 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Caribou Biosciences in a research note on Thursday, October 15th. Bank of America dropped their price target on shares of Caribou Biosciences from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Finally, Brookline Capital Markets lowered shares of Caribou Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 7th.

Read Our Latest Report on Caribou Biosciences

Hedge Funds Weigh In On Caribou Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in Caribou Biosciences during the second quarter worth $13,756,000. Renaissance Technologies LLC boosted its position in Caribou Biosciences by 58.0% during the first quarter. Renaissance Technologies LLC now owns 2,590,497 shares of the company’s stock valued at $4,922,000 after acquiring an additional 950,640 shares during the last quarter. Bank of America Corp DE bought a new stake in Caribou Biosciences during the second quarter valued at $2,483,000. GSA Capital Partners LLP bought a new stake in Caribou Biosciences during the second quarter valued at $816,000. Finally, Green Alpha Advisors LLC raised its position in shares of Caribou Biosciences by 51.4% in the 3rd quarter. Green Alpha Advisors LLC now owns 551,445 shares of the company’s stock worth $700,000 after acquiring an additional 187,121 shares in the last quarter. 77.51% of the stock is owned by institutional investors and hedge funds.

Caribou Biosciences Price Performance

Shares of NASDAQ:CRBU opened at $0.52 on Wednesday. The company has a market cap of $55.64 million, a price-to-earnings ratio of -0.48 and a beta of 2.31. The firm has a 50 day simple moving average of $1.25 and a 200 day simple moving average of $1.66. Caribou Biosciences has a one year low of $0.44 and a one year high of $3.54.

Caribou Biosciences (NASDAQ:CRBU – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.08. Caribou Biosciences had a negative net margin of 1,030.42% and a negative return on equity of 89.11%. The company had revenue of $1.50 million during the quarter, compared to the consensus estimate of $2.28 million. As a group, analysts expect that Caribou Biosciences will post -1.07 EPS for the current year.

Caribou Biosciences Company Profile

(Get Free Report)

Caribou Biosciences, Inc is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. The company uses its proprietary CRISPR-based chRDNA genome-editing platform to engineer immune cells, with an emphasis on allogeneic, or “off-the-shelf,” CAR-T therapies designed to target tumors without requiring cells to be collected from each individual patient.

Caribou’s research and development programs have focused primarily on hematologic malignancies, including investigational CAR-T candidates directed at targets such as CD19 and BCMA.

Recommended Stories